Johnson & Johnson cites rebates and discounts for drug price increases

Why do companies jack up their drug prices each year in U.S.? In recent years, some drugmakers have tried to answer this question with annual statements dressed up as “transparency” reports.

Now, pharma giant Johnson & Johnson has presented its 2022 document, arguing that its rising prices are necessary to cover the growing costs it pays in the form of rebates, discounts and other fees to insurance companies, government programs, distributors and other players in the healthcare system.